Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Are The Growth Projections For The Growth Hormone Deficiency Market Size During 2025–2029?
The growth hormone deficiency market has shown significant expansion in recent years. It is anticipated to increase from $4.06 billion in 2024 to $4.3 billion in 2025, reflecting a compound annual growth rate (CAGR) of 5.8%. This historical growth can be attributed to the growing number of strategic initiatives, a rise in brain tumor incidences, increasing demand for hormone therapies, an expanding elderly population, and enhanced government funding for healthcare.
The growth hormone deficiency market is projected to experience substantial expansion over the upcoming years, reaching $5.38 billion by 2029, driven by a compound annual growth rate (CAGR) of 5.7%. This anticipated growth during the forecast period stems from the increasing occurrence of genetic disorders, a rise in strategic initiatives, intensified research and development efforts, the escalating morbidity associated with Gh disease, and an expanding number of clinical trials. Key trends anticipated in this period encompass technological progress, broader treatment alternatives, improvements in diagnostic methods, recent innovations, and advances in biotechnology.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21197&type=smp
Which Drivers Are Supporting Growth Of The Growth Hormone Deficiency Market?
The increasing occurrence of genetic disorders is anticipated to drive the growth of the growth hormone deficiency market moving forward. Genetic disorders are medical conditions resulting from irregularities or changes in an individual’s DNA, which may be inherited or develop without prior lineage. The heightened prevalence of these disorders is attributed to advancements in diagnostic technology, increased public awareness, rising maternal age, environmental elements causing genetic alterations, population growth, and improved survival outcomes for affected individuals. Growth hormone deficiency treatments are utilized to manage complications related to growth in certain genetic conditions. For example, in December 2022, a report from the Department of Health & Social Care (DHSC), a UK government department, highlighted that by October 2022, around 33,000 whole genome equivalents had been sequenced, showing an average diagnostic yield of 32%, which increased to 61% for specific conditions. Therefore, the expanding prevalence of genetic disorders is a key driver for the growth hormone deficiency market.
How Is The Growth Hormone Deficiency Market Segmented?
The growth hormone deficiencymarket covered in this report is segmented –
1) By Type: Pediatric Growth Hormone Deficiency; Adult Growth Hormone Deficiency
2) By Treatment: Pharmacological Therapy; Recombinant Human Growth Hormone; Human Pituitary Gland Extracts; Surgery
3) By Route Of Administration: Intravenous; Intramuscular; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Online Pharmacy; Retail Pharmacy
5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
Subsegments:
1) By Pediatric Growth Hormone Deficiency: Idiopathic Growth Hormone Deficiency; Genetic Growth Hormone Deficiency; Acquired Growth Hormone Deficiency
2) By Adult Growth Hormone Deficiency: Primary Growth Hormone Deficiency; Secondary Growth Hormone Deficiency
What Trends Are Expected To Drive The Growth Hormone Deficiency Market?
Leading companies within the growth hormone deficiency market are prioritizing the development of innovative solutions, such as unmodified somatropin, for daily pediatric growth hormone deficiency (GHD) treatments. Unmodified somatropin describes the identical growth hormone employed in everyday pediatric GHD treatments, yet it is delivered as a once-weekly dosage using Skytrofa. Illustratively, in September 2023, Ascendis Pharma A/S, a biopharmaceutical company based in Denmark, launched SKYTROFA (lonapegsomatropin) for the once-weekly treatment of pediatric growth hormone deficiency (GHD). This groundbreaking therapy offers improved convenience, better adherence, and potentially superior treatment outcomes when contrasted with traditional daily growth hormone therapies. It holds the distinction of being the first and only FDA-approved once-weekly treatment for pediatric GHD, thereby establishing it as a significant advancement in endocrinology and pediatric care.
Which Leading Companies Dominate The Growth Hormone Deficiency Market Share?
Major companies operating in the growth hormone deficiency market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Eli Lilly and Company, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Genentech Inc., Ipsen Biopharmaceuticals Inc., Opko Health Inc., JCR Pharmaceuticals Co. Ltd., Ferring Pharmaceuticals Inc., Ascendis Pharma A/S, Rani Therapeutics Inc., AnkeBio Co. Ltd., Aeterna Zentaris Inc., Zhongshan Sinobioway Hygene Biomedicine Co. Ltd., Versartis Inc., I-Mab Biopharma Co. Ltd.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/growth-hormone-deficiency-global-market-report
Which Global Regions Are Influencing The Competitive Landscape Of The Growth Hormone Deficiency Market?
North America was the largest region in the growth hormone deficiency market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the growth hormone deficiency market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Growth Hormone Deficiency Market Report:
https://www.thebusinessresearchcompany.com/customise?id=21197&type=smp
Browse Through More Reports Similar to the Global Growth Hormone Deficiency Market 2025, By The Business Research Company
Biosimilar Growth Hormone Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/biosimilar-growth-hormone-global-market-report
Parathyroid Hormones Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/parathyroid-hormones-global-market-report
Biosimilar Hormone Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model